Iron release can be detrimental to the heart, study suggests

A process that releases iron in response to stress may contribute to heart failure, and blocking this process could be a way of protecting the heart, suggests a study in mice published today in eLife.

People with heart failure often have an iron deficiency, leading some scientists to suspect that problems with iron processing in the body may play a role in this condition. The study explains one way that iron processing may contribute to heart failure and suggests potential treatment approaches to protect the heart.

"Iron is essential for many processes in the body including oxygen transport, but too much iron can lead to a build-up of unstable oxygen molecules that can kill cells," says first author Jumpei Ito, who was a Research Associate at the School of Cardiovascular Medicine and Sciences, King's College London, UK, at the time the study was carried out, and is now a visiting scientist based at Osaka Medical College, Japan. "We already knew that iron metabolism undergoes changes in heart failure, but it was unclear whether these changes are helpful or harmful."

To learn more about the role of iron metabolism in heart failure, Ito and colleagues studied mice lacking a protein called the nuclear receptor coactivator 4 (NCOA4), which is necessary to release iron stored in cells when the body's iron levels are low. They found that these mice developed less severe changes associated with heart failure compared to mice with NCOA4. Specifically, the NCOA4-deficient mice did not develop excessive levels of iron or a build-up of unstable oxygen molecules that can lead to cell death in heart failure.

A compound called ferrostatin-1 inhibits the release of stored iron and reduces the accumulation of unstable oxygen molecules. Further experiments by the team showed that treating mice with NCOA4 with ferrostatin-1 can reduce the amount of cell death in heart failure. "Our results suggest that the release of iron can be detrimental to the heart," Ito says. "It can lead to unstable oxygen levels, death in heart cells and ultimately heart failure."

More studies are now needed to understand each step in the process that releases iron and to test whether inhibiting this process could be beneficial to people with heart failure.

Patients with heart failure who are iron deficient are currently treated with iron supplements, which previous studies have shown reduces their symptoms. While our work does not contradict those studies, it does suggest that reducing iron-dependent cell death in the heart could be a potential new treatment strategy for patients."

Kinya Otsu, Senior Author, British Heart Foundation Professor of Cardiology at King's College London

Source:
Journal reference:

Ito, J., et al. (2021) Iron derived from autophagy-mediated ferritin degradation induces cardiomyocyte death and heart failure in mice. eLife. doi.org/10.7554/eLife.62174.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure